GB268

GB268 is a **tri-specific monoclonal antibody** designed to simultaneously target **PD-1 (Programmed cell death protein 1)**, **CTLA-4 (Cytotoxic T-Lymphocyte-Associated Antigen 4)**, and **VEGF (Vascular Endothelial Growth Factor)**. Developed by **Genor Biopharma**, this novel antibody is engineered to enhance antitumor immune activity while reducing toxicity compared to multiple individual or bispecific antibody therapies targeting these pathways. The drug is undergoing early clinical evaluation for the treatment of **advanced solid tumors**, with a primary focus on cancer immunotherapy by blocking immune checkpoints (PD-1 and CTLA-4) and inhibiting angiogenesis (VEGF)[1][2][3][5][9][7][10]. Preclinical studies have demonstrated that GB268 provides enhanced antitumor efficacy and an improved safety profile relative to combinations of monoclonal antibodies targeting the same pathways. The molecule is currently in Phase 1 clinical studies to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[3][5][7][10].